Pluristem's Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe's Horizon 2020 Program
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced that its critical limb ischemia (CLI) program in the European Union has been awarded an $8 million grant. The grant is part of the European Union's Horizon 2020 program, which is its largest Research and Innovation program. The Phase III study of PLX-PAD in CLI will be a collaborative project carried out by an international consortium led by the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) under the...
View full press release